Thrombospondin-1 inhibits alternative complement pathway activation in antineutrophil cytoplasmic antibody-associated vasculitis

Complement activation is a relevant driver in the pathomechanisms of vasculitis. The involved proteins in the interaction between endothelia, complement, and platelets in these conditions are only partially understood. Thrombospondin-1 (TSP-1), found in platelet α-granules and released from activated endothelial cells, interacts with factor H (FH) and vWF. However, to our knowledge, direct regulatory interaction with the complement cascade has not yet been described. Our study shows that TSP-1 is a potent, FH-independent inhibitor of the alternative complement pathway. TSP-1 binds to complement proteins and inhibits cleavage of C3 and C5 and the formation of the membrane attack complex. We validated complement-regulatory function in blood samples from patients with primary complement defects. The physiological relevance of TSP-1 was demonstrated in patients with antineutrophil cytoplasmic antibody-associated vasculitis (AAV) by significantly enhanced TSP-1 staining in glomerular lesions and increased complement activity and NETosis after TSP-1 deficiency in an in vitro and in vivo model of AAV. The complement-inhibiting function of TSP-1 represents an important mechanism in the interaction of endothelia and complement. In particular, the interplay between released TSP-1 and the complement system locally, especially on surfaces, influences the balance between complement activation and inhibition and may be relevant in various vascular diseases.

Authors

Institutions

Publication Details

Journal
Journal of Clinical Investigation
Published
2025-05-08
DOI
https://doi.org/10.1172/jci180062
Citations
4
Primary Topic
Vasculitis and related conditions
Type
article
Field-Weighted Citation Impact
6.07

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Thrombospondin-1 inhibits alternative complement pathway activation in antineutrophil cytoplasmic antibody-associated vasculitis

Swagata Konwar, Christian Gorzelanny, Barbara Zieger, Robert Grosse et al.
4 citations
Journal of Clinical Investigation
Vasculitis and related conditions
6.07
article

Thrombospondin-1 inhibits alternative complement pathway activation in antineutrophil cytoplasmic antibody-associated vasculitis

Swagata Konwar, Christian Gorzelanny, Barbara Zieger, Robert Grosse, Jens Panse, Manuel Rogg, Sophie Schroda, Karsten Häffner, Todor Tschongov, Sílvia Vidal, Christoph Schell, Jessika Kleindienst, Eva L. Decker, Hong Wang, Xiaobo Liu, Martin Pöhl
article en
4 citations

Abstract

Complement activation is a relevant driver in the pathomechanisms of vasculitis. The involved proteins in the interaction between endothelia, complement, and platelets in these conditions are only partially understood. Thrombospondin-1 (TSP-1), found in platelet α-granules and released from activated endothelial cells, interacts with factor H (FH) and vWF. However, to our knowledge, direct regulatory interaction with the complement cascade has not yet been described. Our study shows that TSP-1 is a potent, FH-independent inhibitor of the alternative complement pathway. TSP-1 binds to complement proteins and inhibits cleavage of C3 and C5 and the formation of the membrane attack complex. We validated complement-regulatory function in blood samples from patients with primary complement defects. The physiological relevance of TSP-1 was demonstrated in patients with antineutrophil cytoplasmic antibody-associated vasculitis (AAV) by significantly enhanced TSP-1 staining in glomerular lesions and increased complement activity and NETosis after TSP-1 deficiency in an in vitro and in vivo model of AAV. The complement-inhibiting function of TSP-1 represents an important mechanism in the interaction of endothelia and complement. In particular, the interplay between released TSP-1 and the complement system locally, especially on surfaces, influences the balance between complement activation and inhibition and may be relevant in various vascular diseases.

Journal of Clinical InvestigationVol. 135(13)
Universität Hamburg (DE), University of Freiburg (DE), University Medical Center Freiburg (DE), Integrated Oncology (United States) (US), Okazaki Institute for Integrative Bioscience (JP), University Medical Center Hamburg-Eppendorf (DE), Office of Adolescent Health (US), Institute of Experimental Pharmacology and Toxicology of the Slovak Academy of Sciences (SK), Institute of Pharmacology (CZ), RWTH Aachen University (DE)
Wilhelm Sander-Stiftung, Deutsche Forschungsgemeinschaft, Albert-Ludwigs-Universität Freiburg, Medizinische Fakultät der Albert-Ludwigs-Universität Freiburg
Openalex Percentile: Top 4%
Vasculitis and related conditions
6.07
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.